Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887292 | 0.91 | ALDH1A1 (0.40) | EPHX2LMNAMAPTMAPK1ALDH1A1 | |
| SCHEMBL5886695 | 0.90 | MAPK8 (0.36) | LMNAMAPTMAPK8ALDH1A1AKT1 | |
| SCHEMBL5887202 | 0.90 | BRAF (0.38) | RORCEPHX2LMNAMAPTNAMPT | |
| SCHEMBL5887393 | 0.86 | LMNA (0.44) | LMNAMAPTNAMPTALDH1A1 | |
| SCHEMBL5887036 | 0.84 | EPHX2 (0.39) | RORCEPHX2NR1H4MAPTNAMPT | |
| SCHEMBL5887027 | 0.83 | KMT2A (0.45) | RORCEPHX2NR1H4LMNAMAPT | |
| SCHEMBL5886899 | 0.83 | MAPK8 (0.39) | LMNAMAPK1MAPK8 | |
| SCHEMBL5887408 | 0.83 | PPARG (0.35) | EPHX2NAMPTMAPK8PPARG | |
| SCHEMBL5886996 | 0.82 | MEN1 (0.46) | RORCEPHX2NR1H4LMNAMAPK8 | |
| SCHEMBL5887547 | 0.82 | PRKAB2 (0.41) | RORCEPHX2NR1H4LMNACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | RORC 3073/4885EPHX2 2968/4885NR1H4 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.